ClinicalTrials.gg
CompletedNCT05405725Updated Feb 10, 2026Results posted

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

A Phase 3 interventional study of ENZ215 and Prolia in Postmenopausal Osteoporosis, sponsored by Enzene Biosciences Ltd.. Completed at 48 sites in 7 countries. Open to female participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Enzene Biosciences Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.

Enrollment
22nd of 36
504 · median 543
Started
2022
with 3 others
Phase 3
27 of 36
none open now
Registered
32nd of 36
by date
Lead sponsor
1 of 36
Enzene Biosciences Ltd.

Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 22nd largest by enrollment, is one of 4 that started in 2022, is one of 27 in phase 3, and was the 32nd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Osteoporosis, Postmenopausal with a site in Poland as a file.
02

Study summary

The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis.

The primary goal for the study is

  1. To evaluate the efficacy of ENZ215 when compared to Prolia® in patients with postmenopausal osteoporosis, in terms of change in BMD at the lumbar spine from baseline to Month 12 and
  2. To compare the AUEC of sCTX levels from baseline to Month 6
Read the detailed description

The study will be divided into three periods: Screening period: up to 35 days; Double-blind treatment period of 12 months; and Open-label, switch-over period of six months.

Five hundred four (504) patients (252 patients in each treatment arm) will be enrolled in this study. All eligible patients will be randomized in the double blind treatment period in a 1:1 ratio to receive either ENZ215 or Prolia® (60 mg) subcutaneously (SC) on Day 1 and Month 6. These participants will complete study at 12 months. A PK sub-study will be conducted in a subset of 120 participants with 60 participants in each arm.

A subset of 120 participants randomised to Prolia arm and who completed 12 months of the double-blind treatment period without any significant safety concerns per the Investigator's discretion will be offered to enroll in the open-label, switch-over extension period. After re-consenting for the open-label, switch-over study, the participants will be re-randomised in a 1:1 ratio to receive either ENZ215 or Prolia® (60 mg) SC at Month 12. These participants will complete the study at Month 18.

03

Conditions studied

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to provide voluntary written and able to comply with the protocol requirements
  2. women aged ≥ 55 and ≤ 85 years globally, except for Spain. In Spain specifically refer to the below criteria:

    1. Postmenopausal women aged ≥ 75 and ≤ 85 years with LS T-score ≤ -2.5 or
    2. Postmenopausal women aged ≥ 65 and \< 75 years with LS T-score is ≤ -2.5 and a prior fragility fracture (except for hip fracture), including non-exclusionary vertebral fractures
    3. In both cases (i.e. criteria a and b), it must also be that these are women who present a for the use of bisphosphonates or who do not tolerate the oral route.
  3. Body weight ≥ 50 kg and ≤ 90 kg
  4. Diagnosed with osteoporosis, with absolute BMD consistent with T-scores of ≤ 2.5 and ≥ - 4.0 at the lumbar spine (L1-L4 region) as measured by dual-energy X ray absorptiometry (DXA) at screening
  5. At least 5 years of postmenopausal status confirmed by follicle-stimulating hormone (FSH) levels at screening
  6. At least one hip joint and two vertebrae in L1-L4 region evaluable by DXA
  7. No other medical history, vital signs, physical examination, laboratory profiles as deemed by the Investigator or designee that would pose a risk to participant safety or interfere with the study evaluation, procedures or completion

Exclusion criteria

Exclusion Criteria:

  1. Known to denosumab or any of the of the study drug
  2. Known intolerance to, or malabsorption of calcium or vitamin D supplements
  3. Previous exposure to Prolia® or any other denosumab biosimilar
  4. Previous use of oral bisphosphonates:

    1. Used for 3 or more years cumulatively
    2. If used for \< 3 years, use within the past 12 months prior to screening
  5. Use of intravenous bisphosphonates within the past 5 years prior to screening. If used more than 5 years prior, patients will be excluded if cumulative use was > 3 years.
  6. Use of parathyroid hormone or its derivatives, hormone replacement therapy, romosozumab, selective estrogen-receptor modulators, or tibolone or calcitonin within 12 months prior to enrollment Note: occasional use of intravaginal estrogen treatment is not exclusionary
  7. Any prior use of fluoride or strontium
  8. Systemic (≥ 5 mg prednisone equivalent per day or cumulative dose ≥ 50 mg) for more than 10 days within 3 months prior to enrollment (topical and inhaled corticosteroids are allowed)
  9. Other bone active drugs (i.e. drugs affecting bone metabolism) including heparin, anti epileptics (except for benzodiazepines and pregabalin), antidepressants such as SSRIs, SNRIs, antipsychotics, systemic ketoconazole, adrenocorticotrophic hormone (ACTH), lithium, protease inhibitors, gonadotropin releasing hormone (GnRH) agonists, or anabolic steroids within the past 3 months prior to screening or requiring treatment with these agents during the study.

    Note: Please refer to Section 6.11 for a comprehensive list of prohibited medications

  10. Known sensitivity to drug products derived from mammalian cell lines such as hormones, enzymes, cytokines, bone morphogenic proteins, clotting factors, antibodies, and fusion protein therapeutics. Patients with any known hypersensitivity to complex proteins such as monoclonal antibodies will be excluded.
  11. History of one severe or more than two moderate vertebral fractures per Genant classification as determined by the central reading center
  12. History of hip fracture or bilateral hip replacement
  13. Total hip or femoral neck T-score \<-4.0
  14. History and/or presence of atypical femoral fracture
  15. Presence of any active healing fracture according to the Investigator's assessment
  16. History of any transplant or chronic (including patients on immunosuppressive therapy)
  17. Severe liver dysfunction ( [ALT] or aspartate aminotransferase [AST] > 3 times )
  18. Positive testing for (hepatitis B virus surface antigen [HbsAg]) or (hepatitis C virus antibody [HCV Ab]) virology
  19. Known history of (HIV) infection or positive serology for HIV at screening
  20. Significantly impaired renal function (determined by of \< 45 mL/min/1.73 m2 by the Modification of Diet in Renal Disease (MDRD) formula, as calculated by the central laboratory) or receiving dialysis
  21. Oral or dental conditions:

    1. Osteomyelitis or history and/or presence of osteonecrosis of the jaw (ONJ)
    2. Presence of risk factors for ONJ (e.g., periodontal disease, poorly fitting dentures, poor oral hygiene, invasive dental procedures such as tooth extractions within 6 months prior to screening)
    3. Active dental or jaw condition which requires oral surgery
    4. Planned invasive dental procedure
  22. Major surgery within 8 weeks prior to screening or anticipated major surgery during the study
  23. leukopenia, neutropenia, or anemia as determined by the Investigator or any other clinically significant medical condition or laboratory abnormality that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with adherence to study procedures, study completion, or the interpretation of study results Note: In case of an abnormal laboratory result which in the opinion of the investigator may be an error, is borderline, or indeterminate for inclusion in the study, the investigator may consider repeating the test once in order to rule out laboratory error.
  24. Patient with an active infection or history of infection as follows:

    1. Any active infection for which systemic anti-infectives were used within 4 weeks prior to randomization
    2. A serious infection defined as requiring hospitalization or intravenous anti infectives within 8 weeks prior to randomization
    3. Recurrent or chronic infections or other active infection that, in the opinion of the Investigator, might compromise the safety of the patient
  25. Evidence of any of the following conditions per laboratory test results, medical history, (ECG), DXA, or X-ray review:

    1. Uncontrolled hyperthyroidism or hypothyroidism Note: Clinical significance of abnormal TSH values in patients on stable replacement therapy due to hypothyroidism or on anti-thyroid medication should be assessed and discussed with the Medical Monitor.
    2. History or current hyperparathyroidism or hypoparathyroidism (intact parathyroid hormone levels not within normal range) Note: Mild secondary hyperparathyroidism in the context of vitamin D deficiency may be acceptable upon discussion with the Medical Monitor.
    3. Vitamin D deficiency defined as 25 (OH) vitamin D level \< 20 ng/mL (\< 50 nmol/L) Note: Patients can be enrolled if a repeat test (post supplementation) prior to enrollment shows corrected 25 (OH) vitamin D level ≥ 20 ng/mL (≥ 50 nmol/L).
    4. Current hypocalcemia (albumin-adjusted serum calcium \< 8.0 mg/dL [\< 2.0 mmol/L]) or hypercalcemia (albumin-adjusted serum calcium > 10.6 mg/dL [> 2.62 mmol/L])
    5. History of parathyroid surgery
    6. Any bone or metabolic disease which may affect BMD or interfere with the interpretation of the findings, e.g., osteomalacia, osteogenesis imperfecta, osteopetrosis, achondroplasia, Paget's disease, rheumatoid arthritis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, or malabsorption syndrome
    7. Any , including solid tumors, and hematologic malignancies (except basal cell carcinoma and squamous cell carcinomas of the skin, cervical, or breast ductal carcinoma in situ, that have been completely excised and are considered cured) within the last 5 years
    8. Known or suspected history of alcoholism (including heavy drinking defined as consuming more than 3 drinks on one day or more than 7 drinks per week) or substance abuse within the past 12 months prior to the first dosing that the Investigator believes would interfere with understanding or completing the study
    9. Current heavy smoking, defined as smoking 20 or more cigarettes per day.
    10. Participated in any other clinical study in last 30 days prior to screening
    11. History and/or presence of significant cardiac disease as per Investigator's discretion, including but not restricted to:

    i. History of cardiac arrhythmia or long syndrome or ECG abnormalities at screening indicating significant risk for safety (e.g., that required hospitalization, emergency cardioversion, or defibrillation) ii. History and/or presence of myocardial infarction within 6 months before screening iii. History and/or presence of (NYHA) class III or IV heart failure

  26. Suspected signs and symptoms of COVID-19/confirmed COVID-19 or with recent history of travel/contact (less than 2 weeks from screening) with any COVID-19 positive patient/isolation/quarantine
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    ENZ215

    ENZ215 Injection: - 60 mg denosumab administered as a single subcutaneous injection at day 1 and at month 6

    Biological: ENZ215

  • Active comparator
    Prolia

    Prolia Injection: - 60 mg denosumab administered as a single subcutaneous injection at day 1 and at month 6

    Biological: Prolia

Interventions

  • BiologicalENZ215

    Enrolled women with postmenopausal osteoporosis receive ENZ215 (60mg)

  • BiologicalDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enrolled women with postmenopausal osteoporosis receive Prolia

06

What researchers measure

Primary outcomes

  1. To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine.

    The percentage change in BMD at lumbar spine (L1-L4 region) measured by DXA from baseline to month 12 and the mean (±SD) percentage change over time is displayed for the ITT set. The ITT analysis set consisted of all randomised participants who received at least one dose of study intervention in the double-blind treatment period. In the ITT analysis set, treatment was assigned based on the study intervention to which participants were randomised, regardless of which treatment they actually received.

    Time frame: Month 12

  2. Area Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) Levels

    The AUEC of %CfB in sCTX of ENZ215 was assessed as part of pharmacodynamics assessment to compare with Prolia® in female participants with postmenopausal osteoporosis. This outcome measure was assessed for initial 6 months

    Time frame: Month 6

Secondary outcomes

  1. To Compare the Immunogenicity Potential of ENZ215 and Prolia

    ADAs incidence such as ADA positive, ADA negative, NAB positive, NAB negative assessed at baseline and different timepoints from 1 month to 12 months and during open-label switch over period assessed. Subjects were considered as post-treatment ADA and NAb positive if they had at least one "Positive" ADA and NAb result after the first drug exposure. Post-treatment ADA and NAb status was determined regardless of the results at pre-dose.

    Time frame: From Baseline to Month 12 for Double blind treatment period and to month 18 for Open label switchover treatment period

  2. To Compare the Pharmacokinetics of ENZ215 and Prolia

    Comparison of PK parameters of ENZ215 and Prolia over 12 months

    Time frame: 12 months

  3. Serum Procollagen Type 1 N-terminal Propeptide (sP1NP) Levels

    Percent change from baseline in type 1 N-terminal propeptide (sP1NP) levels at 6 months

    Time frame: Month 6

  4. To Compare the Change in BMD at the Lumbar Spine at Month 6

    Percentage change in BMD at lumbar spine measured by DXA from baseline at month 6

    Time frame: Baseline to Month 6

  5. To Compare the Change in BMD at Total Hip and Femoral Neck

    Percentage change in BMD at total hip and femoral neck measured by DXA from baseline to Month to predefined timepoint

    Time frame: Baseline to Month 6 and Month 12

07

Results

Posted Feb 10, 2026

Participant flow

A total of 504 participants were randomized in the study at 44 centers across 7 countries (Bulgaria, Czech Republic, Denmark, Lithuania, Poland, Spain and Serbia) between July 2022 and January 2023.

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneENZ215ProliaProlia + ENZ215Prolia + Prolia
Started25325100
Completed23323600
Not completed201500
Open-label Switchover Period
Participant flow — Open-label Switchover Period
MilestoneENZ215ProliaProlia + ENZ215Prolia + Prolia
Started006060
Completed006060
Not completed0000

Outcome measures

PrimaryTo Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine.

The percentage change in BMD at lumbar spine (L1-L4 region) measured by DXA from baseline to month 12 and the mean (±SD) percentage change over time is displayed for the ITT set. The ITT analysis set consisted of all randomised participants who received at least one dose of study intervention in the double-blind treatment period. In the ITT analysis set, treatment was assigned based on the study intervention to which participants were randomised, regardless of which treatment they actually received.

Time frame:
Month 12
Reported as:
Least squares mean · % Change from Baseline
To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine.
% Change from BaselineENZ215Prolia
To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine.5.350 ± 0.31525.533 ± 0.3108
Statistical analysis
  • ENZ215 vs Prolia · Mean difference (final values): -0.195 · 95% CI -0.9167 to 0.5259
PrimaryArea Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) Levels

The AUEC of %CfB in sCTX of ENZ215 was assessed as part of pharmacodynamics assessment to compare with Prolia® in female participants with postmenopausal osteoporosis. This outcome measure was assessed for initial 6 months

Time frame:
Month 6
Reported as:
Geometric mean · h*%
Area Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) Levels
h*%ENZ215Prolia
Area Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) Levels347382.787 (340087.2488 to 354834.8289)345858.423 (338640.7259 to 352229.9557)
Statistical analysis
  • ENZ215 vs Prolia · Geometric mean ratio: 1.004 · 90% CI 0.9795 to 1.0299
SecondaryTo Compare the Immunogenicity Potential of ENZ215 and Prolia

ADAs incidence such as ADA positive, ADA negative, NAB positive, NAB negative assessed at baseline and different timepoints from 1 month to 12 months and during open-label switch over period assessed. Subjects were considered as post-treatment ADA and NAb positive if they had at least one "Positive" ADA and NAb result after the first drug exposure. Post-treatment ADA and NAb status was determined regardless of the results at pre-dose.

Time frame:
From Baseline to Month 12 for Double blind treatment period and to month 18 for Open label switchover treatment period
Reported as:
Count of participants · Participants
To Compare the Immunogenicity Potential of ENZ215 and Prolia
ParticipantsENZ215ProliaProlia + ENZ215Prolia + Prolia
ADA positive subjects2522476060
nAb positive subjects1500
ADA Negative0000
Nab Negative2512426060
SecondaryTo Compare the Pharmacokinetics of ENZ215 and Prolia

Comparison of PK parameters of ENZ215 and Prolia over 12 months

Time frame:
12 months
Reported as:
Geometric mean · h*ng/mL
To Compare the Pharmacokinetics of ENZ215 and Prolia
h*ng/mLENZ215Prolia
AUC (0-1M)3220000 ± 40.43000000 ± 33.1
AUC (0-3M)7260000 ± 45.76450000 ± 35.2
AUC (0-6M)8420000 ± 48.07460000 ± 36.7
AUC (6-12M)312000 ± 232.1301000 ± 130.5
SecondarySerum Procollagen Type 1 N-terminal Propeptide (sP1NP) Levels

Percent change from baseline in type 1 N-terminal propeptide (sP1NP) levels at 6 months

Time frame:
Month 6
Reported as:
Mean · Percentage Change from baseline
Serum Procollagen Type 1 N-terminal Propeptide (sP1NP) Levels
Percentage Change from baselineENZ215Prolia
Month 1 (Day 15)8.3369 ± 19.51707.5198 ± 17.9673
Month 1 (Day 30)-17.7485 ± 17.1910-18.3767 ± 23.4844
Month 3 (Day 90)-75.7738 ± 15.4099-74.5419 ± 16.6630
Month 6 (Day 180)-69.7567 ± 19.4086-69.1690 ± 22.8816
SecondaryTo Compare the Change in BMD at the Lumbar Spine at Month 6

Percentage change in BMD at lumbar spine measured by DXA from baseline at month 6

Time frame:
Baseline to Month 6
Reported as:
Least squares mean · Percentage Change
To Compare the Change in BMD at the Lumbar Spine at Month 6
Percentage ChangeENZ215Prolia
To Compare the Change in BMD at the Lumbar Spine at Month 63.615 ± 0.26434.004 ± 0.2596
SecondaryTo Compare the Change in BMD at Total Hip and Femoral Neck

Percentage change in BMD at total hip and femoral neck measured by DXA from baseline to Month to predefined timepoint

Time frame:
Baseline to Month 6 and Month 12
Reported as:
Least squares mean · Percentage Change
To Compare the Change in BMD at Total Hip and Femoral Neck
Percentage ChangeENZ215Prolia
Month 6-BMD at Total Hip2.222 ± 0.20422.327 ± 0.2005
Month 6-BMD at Femoral Neck1.700 ± 0.24611.688 ± 0.2420
Month 12-BMD at Total Hip2.534 ± 0.20442.935 ± 0.2012
Month 12-BMD at Femoral Neck1.826 ± 0.29052.589 ± 0.2866

Adverse events

Collected over From Baseline to Month 12 for participants in main study and up to 18 months for participants in Open label switch over period. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ENZ2150/253 (0%)16/253 (6.3%)115/253 (45.5%)
Prolia1/251 (0.4%)15/251 (6%)122/251 (48.6%)
Prolia + ENZ2150/60 (0%)0/60 (0%)23/60 (38.3%)
Prolia + Prolia0/60 (0%)0/60 (0%)23/60 (38.3%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventENZ215ProliaProlia + ENZ215Prolia + Prolia
Radius FractureInjury, poisoning and procedural complications3/2531/2510/600/60
Wrist FractureInjury, poisoning and procedural complications2/2530/2510/600/60
Ankle FractureInjury, poisoning and procedural complications1/2531/2510/600/60
Craniofacial fractureInjury, poisoning and procedural complications0/2531/2510/600/60
Foot FractureInjury, poisoning and procedural complications0/2531/2510/600/60
Forearm FractureInjury, poisoning and procedural complications0/2531/2510/600/60
Lower Limb FractureInjury, poisoning and procedural complications0/2531/2510/600/60
COVID-19Infections and infestations0/2531/2510/600/60
CystitisInfections and infestations0/2531/2510/600/60
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2531/2510/600/60
Most frequent other events
Showing 10 of 76
Most frequent other events
EventENZ215ProliaProlia + ENZ215Prolia + Prolia
NasopharyngitisInfections and infestations18/25322/2515/605/60
Upper Respiratory Tract InfectionInfections and infestations11/25316/2512/600/60
HeadacheNervous system disorders6/25313/2510/600/60
HypertensionVascular disorders9/25312/2510/600/60
COVID-19Infections and infestations5/25312/2511/601/60
BronchitisInfections and infestations11/2536/2510/602/60
ArthralgiaMusculoskeletal and connective tissue disorders9/2539/2510/600/60
Spinal PainMusculoskeletal and connective tissue disorders5/2534/2512/600/60
PharyngitisInfections and infestations6/2533/2512/600/60
Urinary Tract InfectionInfections and infestations8/2538/2510/600/60

Baseline characteristics

Postmenopausal Women with Osteoporosis aged ≥ 55 and ≤ 85 years

Age, Categorical
Age, Categorical(Participants)ENZ215ProliaTotal
<=18 years000
Between 18 and 65 years171171342
>=65 years8280162
Sex: Female, Male
Sex: Female, Male(Participants)ENZ215ProliaTotal
Female253251504
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ENZ215ProliaTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White253251504
More than one race000
Unknown or Not Reported000
08

Study locations

48 sites
  • University Hospital
    Plovdiv, 4027, Bulgaria
  • Medical Center Teodora,
    Rousse, 7000, Bulgaria
  • DCC XVII-Sofia EOOD
    Sofia, 1505, Bulgaria
  • Research Center(Medical Center Synexus Sofia EOOD)
    Sofia, 1784, Bulgaria
  • Research Center
    Brno, 60200, Czechia
  • G-CENTRUM Olomouc
    Horní Město, Czechia
  • Research Center
    Pardubice, Czechia
  • University Hospital.
    Pilsen, Czechia
  • Synexus Czech
    Prague, 12000, Czechia
  • Clinic
    Prague, 14800, Czechia
  • Fakultni nemocnice v Motole
    Prague, Czechia
  • MEDICAL PLUS s.r.o.
    Uherské Hradiště, Czechia
  • Sydvestjysk Sygehus Esbjerg
    Esbjerg, 6700, Denmark
  • JSC Saules seimos medicinos ce
    Kaunas, 49449, Lithuania
  • Hospital of Lithuanian University of Health Sciences Kauno klinikos
    Kaunas, 50161, Lithuania
  • Kaunas City Polyclinic
    Kaunas, 51270, Lithuania
  • Lithuanian University of Health Sciences Hospital
    Kaunas, Lithuania
  • Republican Siauliai Hospital
    Šiauliai, Lithuania
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, 08661, Lithuania
  • National Osteoporosis Center
    Vilnius, 09310, Lithuania
  • Osteo-Medic S.C. A Racewicz
    Bialystok, Poland
  • Szpital Uniwersytecki
    Bydgoszcz, Poland
  • Centrum Medyczne Pratia Czestochowa
    Częstochowa, Poland
  • Synexus Polska
    Częstochowa, Poland
  • Synexus Polska
    Gdansk, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, Poland
  • Synexus Polska
    Gdynia, Poland
  • Silmedic sp. z o.o.,ul. Gen. Wladyslawa Sikorskiego
    Katowice, Poland
  • Synexus Polska
    Katowice, Poland
  • ETG Kielce, ul. Zagorska
    Kielce, Poland
  • Krakowskie Centrum Medyczne
    Krakow, Poland
  • ETG Lodz, ul. Pilota Stanislawa Wigury
    Lodz, Poland
  • Synexus Polska
    Lodz, Poland
  • ETG Lublin, ul. Kunickiego
    Lublin, Poland
  • Twoja Przychodnia Nowosolskie Centrum Medyczne,
    Nowa Sól, Poland
  • Prywatna Praktyka Lekarska
    Poznan, Poland
  • Synexus Polska
    Poznan, Poland
  • Twoja Przychodnia PCM
    Poznan, Poland
  • ETG Siedlce
    Siedlce, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, Poland
  • Synexus Polska
    Warsaw, Poland
  • Synexus Polska
    Wroclaw, Poland
  • Centrum Medyczne Kuba- Med
    Zamość, Poland
  • Institute for Rheumatology
    Belgrade, Serbia
  • Zvezdara University Medical Center
    Belgrade, Serbia
  • Institute for Treatment and Rehabilitation Niska Banja
    Niška Banja, Serbia
  • Clinical Hospital Centre Bezanijska Kosa
    Zemun, Serbia
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2024, 24 months.

Results were first posted in Feb 2026, 1 year 6 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 24 months is close to that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2022
First posted
Jun 6, 2022
StartActual
Jul 4, 2022
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 18, 2024
Results first posted
Feb 10, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05405725
Lead sponsor
Enzene Biosciences Ltd.
Collaborators
Alkem Laboratories Ltd
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Jul 4, 2022
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024
Results posted
Feb 10, 2026
Last update
Feb 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion